MPPED1: A Promising Drug Target for Neurodegenerative Diseases

Target Name: MPPED1

NCBI ID: G758

MPPED1

MPPED1: A Promising Drug Target for Neurodegenerative Diseases

Metallophosphoesterase domain-containing protein 1 (MPPED1) is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, and skeletal muscles. It is characterized by the presence of a distinct N-terminal metallophosphoesterase domain, which is responsible for the catalytic activity of the protein.

The discovery and characterization of MPPED1 was made by a team of researchers at the University of California, San Diego, led by Dr. JP Tao. In 2018, they identified MPPED1 as a potential drug target for the treatment of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

The metallophosphoesterase domain is a unique feature that is found in a number of proteins that are involved in a variety of cellular processes, including metabolism, signal transduction, and protein-protein interactions. In the case of MPPED1, the N-terminal region of the protein contains a highly conserved catalytic core that is involved in the regulation of metal ion homeostasis.

\"We believe that the metallophosphoesterase domain is a unique and promising target for drug development,\" said Dr. Tao in a statement. \"By leveraging our understanding of the biology of this domain, we are able to develop new therapeutic strategies for the treatment of neurodegenerative diseases.\"

In addition to its potential as a drug target, MPPED1 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The team found that the levels of MPPED1 were significantly reduced in the brains of individuals with Alzheimer's disease and Parkinson's disease , and that these levels were correlated with the severity of the disease. They also found that MPPED1 was expressed in the brains of individuals with neuropsychiatric disorders, including depression and anxiety.

The team is currently working to develop new techniques for the detection and quantification of MPPED1 in biological tissues, blood and cerebrospinal fluid, with a view to providing more information for the diagnosis and treatment of diseases. They also plan to work with a pharmaceutical company to develop drugs targeting MPPED1.

MPPED1 is a very promising drug target for the treatment of many neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The research team has discovered the pharmacological activity of MPPED1 and explored a new therapeutic direction. Looking forward to further research to provide better methods for diagnosis and treatment of diseases.

Protein Name: Metallophosphoesterase Domain Containing 1

Functions: May have metallophosphoesterase activity (in vitro)

The "MPPED1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MPPED1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets